Statistically significantly better analgesic efficacy over 48 hours vs tramadol hydrochloride, celecoxib, and placebo*1


*As demonstrated by
summed pain intensity
difference over 48 hours
(SPID48) at the doses studied
in a pivotal Phase 3 trial.

Co-crystallization image

A unique co-crystal that helps appropriate patients manage acute pain

SEGLENTIS leverages 4 complementary mechanisms of analgesia in the central and peripheral pathways.

Eligible patients may pay as little as $25 for SEGLENTIS

Certain rules and restrictions apply.

SEGLENTIS has convenient 12-hour dosing1

Crystal Clear:
A SEGLENTIS education hub

Access more information about acute pain management and SEGLENTIS

Sign up for more
information and important updates about SEGLENTIS


SEGLENTIS contains tramadol hydrochloride, an opioid agonist, and celecoxib, a nonsteroidal anti-inflammatory drug, and is indicated for the management of acute pain in adults that is severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

Limitations of Use

Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, reserve SEGLENTIS for use in patients for whom alternative treatment options [e.g., non-opioid analgesics]:


  1. SEGLENTIS [prescribing information]. Montgomery, AL: Kowa Pharmaceuticals America, Inc.; October 2021.